The Microbiome in PDAC—Vantage Point for Future Therapies?
Microorganisms have been increasingly implicated in the pathogenesis of malignant diseases, potentially affecting different hallmarks of cancer. Despite the fact that we have recently gained tremendous insight into the existence and interaction of the microbiome with neoplastic cells, we are only be...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/23/5974 |
| _version_ | 1797463510942220288 |
|---|---|
| author | Nina Pfisterer Catharina Lingens Cathleen Heuer Linh Dang Albrecht Neesse Christoph Ammer-Herrmenau |
| author_facet | Nina Pfisterer Catharina Lingens Cathleen Heuer Linh Dang Albrecht Neesse Christoph Ammer-Herrmenau |
| author_sort | Nina Pfisterer |
| collection | DOAJ |
| description | Microorganisms have been increasingly implicated in the pathogenesis of malignant diseases, potentially affecting different hallmarks of cancer. Despite the fact that we have recently gained tremendous insight into the existence and interaction of the microbiome with neoplastic cells, we are only beginning to understand and exploit this knowledge for the treatment of human malignancies. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive solid tumor with limited therapeutic options and a poor long-term survival. Recent data have revealed fascinating insights into the role of the tumoral microbiome in PDAC, with profound implications for survival and potentially therapeutic outcomes. In this review, we outline the current scientific knowledge about the clinical and translational role of the microbiome in PDAC. We describe the microbial compositions in healthy and tumoral pancreatic tissue and point out four major aspects of the microbiome in PDAC: pathogenesis, diagnosis, treatment, and prognosis. However, caution must be drawn to inherent pitfalls in analyzing the intratumoral microbiome. Among others, contamination with environmental microbes is one of the major challenges. To this end, we discuss different decontamination approaches that are crucial for clinicians and scientists alike to foster applicability and physiological relevance in this translational field. Without a definition of an exact and reproducible intratumoral microbial composition, the exploitation of the microbiome as a diagnostic or therapeutic tool remains theoretical. |
| first_indexed | 2024-03-09T17:51:45Z |
| format | Article |
| id | doaj.art-d6c2227d72b543bb81ead82ea1442c4b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T17:51:45Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d6c2227d72b543bb81ead82ea1442c4b2023-11-24T10:41:44ZengMDPI AGCancers2072-66942022-12-011423597410.3390/cancers14235974The Microbiome in PDAC—Vantage Point for Future Therapies?Nina Pfisterer0Catharina Lingens1Cathleen Heuer2Linh Dang3Albrecht Neesse4Christoph Ammer-Herrmenau5Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, GermanyDepartment of Medical Bioinformatics, University Medical Center Goettingen, 37075 Goettingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, GermanyMicroorganisms have been increasingly implicated in the pathogenesis of malignant diseases, potentially affecting different hallmarks of cancer. Despite the fact that we have recently gained tremendous insight into the existence and interaction of the microbiome with neoplastic cells, we are only beginning to understand and exploit this knowledge for the treatment of human malignancies. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive solid tumor with limited therapeutic options and a poor long-term survival. Recent data have revealed fascinating insights into the role of the tumoral microbiome in PDAC, with profound implications for survival and potentially therapeutic outcomes. In this review, we outline the current scientific knowledge about the clinical and translational role of the microbiome in PDAC. We describe the microbial compositions in healthy and tumoral pancreatic tissue and point out four major aspects of the microbiome in PDAC: pathogenesis, diagnosis, treatment, and prognosis. However, caution must be drawn to inherent pitfalls in analyzing the intratumoral microbiome. Among others, contamination with environmental microbes is one of the major challenges. To this end, we discuss different decontamination approaches that are crucial for clinicians and scientists alike to foster applicability and physiological relevance in this translational field. Without a definition of an exact and reproducible intratumoral microbial composition, the exploitation of the microbiome as a diagnostic or therapeutic tool remains theoretical.https://www.mdpi.com/2072-6694/14/23/5974microbiomepancreatic ductal adenocarcinomacontaminationbiomarker |
| spellingShingle | Nina Pfisterer Catharina Lingens Cathleen Heuer Linh Dang Albrecht Neesse Christoph Ammer-Herrmenau The Microbiome in PDAC—Vantage Point for Future Therapies? Cancers microbiome pancreatic ductal adenocarcinoma contamination biomarker |
| title | The Microbiome in PDAC—Vantage Point for Future Therapies? |
| title_full | The Microbiome in PDAC—Vantage Point for Future Therapies? |
| title_fullStr | The Microbiome in PDAC—Vantage Point for Future Therapies? |
| title_full_unstemmed | The Microbiome in PDAC—Vantage Point for Future Therapies? |
| title_short | The Microbiome in PDAC—Vantage Point for Future Therapies? |
| title_sort | microbiome in pdac vantage point for future therapies |
| topic | microbiome pancreatic ductal adenocarcinoma contamination biomarker |
| url | https://www.mdpi.com/2072-6694/14/23/5974 |
| work_keys_str_mv | AT ninapfisterer themicrobiomeinpdacvantagepointforfuturetherapies AT catharinalingens themicrobiomeinpdacvantagepointforfuturetherapies AT cathleenheuer themicrobiomeinpdacvantagepointforfuturetherapies AT linhdang themicrobiomeinpdacvantagepointforfuturetherapies AT albrechtneesse themicrobiomeinpdacvantagepointforfuturetherapies AT christophammerherrmenau themicrobiomeinpdacvantagepointforfuturetherapies AT ninapfisterer microbiomeinpdacvantagepointforfuturetherapies AT catharinalingens microbiomeinpdacvantagepointforfuturetherapies AT cathleenheuer microbiomeinpdacvantagepointforfuturetherapies AT linhdang microbiomeinpdacvantagepointforfuturetherapies AT albrechtneesse microbiomeinpdacvantagepointforfuturetherapies AT christophammerherrmenau microbiomeinpdacvantagepointforfuturetherapies |